Cellular Biomedicine Raises $14.5 Million for CAR-T Immunotherapy, Stem Cells

Cellular Biomedicine Group, a China-US biopharma, added $14.5 million into its treasury through two private placements, one to key executives and the other to outside investors. CBMG is developing a CAR-T immunotherapy for cancer indications and an off-the-shelf stem cell treatment for knee arthritis.  Before the transaction, CBMG had $16 million of cash. The company plans to use the funds for clinical trials and drug development. More details.... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //